In October 25th – 27th, 2018 in Shanghai, China, during the 10th Annual Natural Health Conference (CNIC), dr Katarzyna Maresz, president of International Science and Health Foundation, presented the talk focused on vitamin K2 and CV health.
Dr Katarzyna Maresz, President of the ISHF, is the co-author of the article “Decreased Levels of Circulating Carboxylated Osteocalcin in Children with Low Energy Fractures: A Pilot Study” published in the journal Nutrients. Below we present an abstract and a link to the entire text.
OBJECTIVE: In the past decades, an increased interest in the roles of vitamin D and K has become evident, in particular in relation to bone health and prevention of bone fractures. The aim of the current study was to evaluate vitamin D and K status in children with low-energy fractures and in children without fractures.
METHODS: The study group of 20 children (14 boys, 6 girls) aged 5 to 15 years old, with radiologically confirmed low-energy fractures was compared with the control group of 19 healthy children (9 boys, 10 girls), aged 7 to 17 years old, without fractures. Total vitamin D (25(OH)D3 plus 25(OH)D2), calcium, BALP (bone alkaline phosphatase), NTx (N-terminal telopeptide), and uncarboxylated (ucOC) and carboxylated osteocalcin (cOC) serum concentrations were evaluated. Ratio of serum uncarboxylated osteocalcin to serum carboxylated osteocalcin ucOC:cOC (UCR) was used as an indicator of bone vitamin K status. Logistic regression models were created to establish UCR influence for odds ratio of low-energy fractures in both groups.
RESULTS: There were no statistically significant differences in the serum calcium, NTx, BALP, or total vitamin D levels between the two groups. There was, however, a statistically significant difference in the UCR ratio. The median UCR in the fracture group was 0.471 compared with the control group value of 0.245 (p < 0.0001). In the logistic regression analysis, odds ratio of low-energy fractures for UCR was calculated, with an increased risk of fractures by some 78.3 times. CONCLUSIONS: In this pilot study, better vitamin K status expressed as the ratio of ucOC:cOC-UCR—is positively and statistically significantly correlated with lower rate of low-energy fracture incidence.
The International Science and Health Foundation (ISHF) is thrilled to announce a new collaboration with renowned Chinese researcher, Professor Xiaodong Cheng, MD, PhD, with the goal of illuminating the benefits of Vitamin K2 for cancer treatments.
Dr. Cheng is currently a full Professor of Immunology, Oncology, and Integrative Medicine; Director of Institute of Clinical Immunology, Yue-Yang Hospital of Integrative Medicine, Shanghai University of Traditional Chinese Medicine (TCM). He is the “Oriental Outstanding Scholar” Honorable Professor and the “Pu-jiang Outstanding Talent” Distinguished Professor in China. He is a guest professor of The Atlantic Institute of Oriental Medicine, USA, and also a guest professor of University of Joseph Fourier in France. He is not only a basic research scientist but also a clinical physician of TCM as well.
On a recent trip to Shanghai, Dr. Katarzyna Maresz, president of the ISHF, had an opportunity to meet with Dr. Cheng. He discussed that his research interests are currently focused on:
- targeting therapy to cancer by Chinese medical herbs in combination with monoclonal antibody and its related immunological mechanisms;
- immunopathogenesis of CNS autoimmune inflammatory diseases; and
- clinical trial and basic study on therapeutic approaches with traditional Chinese medicine in treating cancer diseases.
With this focus in mind, Drs. Cheng and Maresz began an in-depth discussion of Vitamin K2 and the robust research supporting its benefits for human health and the ongoing research confirming new benefits.
The ISHF will work in tandem with Dr. Cheng’s team at the Institute of Clinical Immunology in Shanghai, lending insight and understanding around the current research of Vitamin K2.
“Based on Vitamin K2’s mechanism of action, we believe it shows great potential for possible cancer therapies,” says Dr. Katarzyna Maresz, ISHF president. “We are honored that Dr. Cheng also recognizes this potential and wants to lend his expertise to exploring clinical confirmation of these benefits.”